<DOC>
	<DOCNO>NCT00002597</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell . Androgens stimulate growth prostate cancer cell . Hormone therapy use flutamide , goserelin , leuprolide may fight prostate cancer reduce production androgen . It yet know regimen antiandrogen therapy effective prostate cancer . PURPOSE : Randomized phase III trial study effectiveness radiation therapy without antiandrogen therapy treat patient stage I stage II prostate cancer .</brief_summary>
	<brief_title>Radiation Therapy With Without Antiandrogen Therapy Treating Patients With Stage I Stage II Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Compare overall disease-specific survival local and/or distant clinical relapse rate patient locally confine carcinoma prostate treat goserelin plus flutamide used cytoreductive agent prior definitive radiotherapy v radiotherapy alone . II . Compare regimens term freedom prostate specific antigen ( PSA ) failure , second clinical relapse , second PSA relapse patient . III . Compare prostate rebiopsy result patient 2 year . IV . Determine effect goserelin flutamide therapy sexual function patient . OUTLINE : This randomize , multicenter study . Patients stratify PSA level ( le 4 vs 4-20 ) , tumor differentiation ( good v moderate v poor ) , nodal status ( N0 v Nx ) , participate center . Patients randomize one two treatment arm . Arm I : Patients receive oral flutamide 3 time day goserelin subcutaneously every 4 week , time release injection ( intramuscular leuprolide may substitute goserelin ) , begin 2 month prior radiotherapy continue completion radiotherapy . Patients undergo radiotherapy daily 4-5 day per week almost 8 week . Arm II : Patients undergo radiotherapy , arm I . Patients follow every 3 month remainder first year , every 4 month 1 year , every 6 month 3 year annually thereafter . PROJECTED ACCRUAL : A total 1980 patient accrue study within 5 year .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Flutamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma prostate Clinical stage T1b/1c/2a/2b , Nx N0 , M0 disease ( stage I II ) Nodes consider negative image method classify Nx ; consider negative surgical sampling classify N0 PSA great 20 PATIENT CHARACTERISTICS : Age : Any age Performance status : Karnofsky 70100 % Hematopoietic : Not specify Hepatic : Alanine aminotransferase ( ALT ) great 2 time upper limit normal Renal : Not specify Other : No major medical psychiatric illness would prevent compliance No malignancy past 5 year except basal squamous cell skin carcinoma ( minimum 2 year since squamous cell carcinoma ) PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : At least 60 day since prior finasteride prostate hypertrophy At least 90 day since prior testosterone No prior hormonal therapy Radiotherapy : No prior radiotherapy Surgery : No prior radical surgery cryosurgery carcinoma prostate</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
</DOC>